Possible biomarkers in animals could warn Ebola virus infection prior to the appearance of symptoms according to research published in the journal Science Translational Medicine. The work an alliance between the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and Boston University (BU), could make the inroads for advancing diagnostic tools to recognize EBOV infection even in humans even prior to symptoms appearing. Such tools would be critical in restricting the escalation of disease where there are instances of familiar possible exposure to the virus according to USAMRIID investigator Sandra L. Bixler, Ph.D., the paper’s co-first author.
Bixler reiterated prior grown animal models of EBOV infection possess a critical disease course existing only 7-10 to days on average. This makes curative involvement demanding since the time period for regulating remedy is very short. In appendage, such models are depended on excessive viral measures and are undeviatingly deadly, which does not cast back the variable and approximately enhanced time to disease arrival seen in humans.
Bixler commented those models be compatible for testing vaccines and therapeutics but as the human infection is concerned they are on a different wavelength what we see practically especially the experience with Ebola virus disease upsurge in Western Africa.
So Bixler and USAMRIID colleague Arthur J. Goff, PhD pronounced to probe unconventional models that could still reproduce human infection while enlarging the disease course. In place of exacting the animals via injection which is a normal laboratory model, they examined the intranasal route which would be more prone to occur where people may be open to contaminated body fluids.